Collagenase-3 (MMP-13) is characterized by an exceptionally wide substrate speci®city and restricted expression. MMP-13 is speci®cally expressed by transformed human keratinocytes in squamous cell carcinomas in vivo and its expression correlates with their invasion capacity. Here, we show, that interferon-g (IFN-g) markedly inhibits expression of MMP-13 by human cutaneous SCC cells (UT-SCC-7) and by ras-transformed human epidermal keratinocytes (A-5 cells) at the transcriptional level. In addition, IFN-g inhibits collagenase-1 (MMP-1) expression in these cells. IFN-g abolished the enhancement of MMP-13 and MMP-1 expression by transforming growth factor-b (TGF-b) and tumor necrosis factor-a (TNF-a), and inhibited invasion of A-5 cells through type I collagen. IFN-g also rapidly and transiently activates extracellular signal-regulated kinase 1,2 (ERK1,2) and blocking ERK1,2 pathway (Raf/MEK1,2/ERK1,2) by speci®c MEK1,2 inhibitor PD98059 partially (by 50%) prevents Ser-727 phosphorylation of STAT1 and suppression of MMP-13 expression by IFN-g. Furthermore, Ser-727 phosphorylation of STAT1 by ERK1,2, or independently of ERK1,2 activation is associated with marked reduction in MMP-13 expression. These observations identify a novel role for IFN-g as a potent inhibitor of collagenolytic activity and invasion of transformed squamous epithelial cells, and show that inhibition of MMP-13 expression by IFN-g involves activation of ERK1,2 and STAT1. Oncogene (2000) 19, 248 ± 257.
Introduction
Invasion and metastasis of malignantly transformed cells involves detachment of cells from primary tumor, controlled degradation of structural barriers, such as basement membrane and collagenous extracellular matrix (ECM), and migration of cells through degraded matrix (Stetler-Stevenson et al., 1993) . Matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases collectively capable of degrading essentially all ECM components and they obviously play an important role in matrix degradation in tumor invasion and tumor-induced angiogenesis (StetlerStevenson et al., 1993; KaÈ haÈ ri and Saarialho-Kere, 1999; Westermarck and KaÈ haÈ ri, 1999) . At present, 18 human members of the MMP gene family are known and they are divided into subgroups of collagenases, gelatinases, stromelysins, membrane-type MMPs, and other MMPs according to their structure and substrate speci®city (KaÈ haÈ ri and Saarialho- Westermarck and KaÈ haÈ ri, 1999) . Members of the collagenase subgroup, i.e. collagenase-1 (MMP-1), collagenase-2 (MMP-8), and collagenase-3 (MMP-13) are the principal neutral proteinases capable of degrading native ®brillar collagens in the extracellular space. They cleave type I, II, and III collagens at a speci®c site generating 3/4 N-terminal and 1/4 C-terminal fragments, which then denature in physiologic temperature and are further degraded by other MMPs, e.g. gelatinases (see KaÈ haÈ ri and Saarialho-Kere, 1999; Westermarck and KaÈ haÈ ri, 1999) . MMP-13 also cleaves type I collagen in N-terminal non-helical telopeptide (Krane et al., 1996) , displays potent gelatinase activity Mitchell et al., 1996) , and degrades type IV, X and XIV collagens, large tenascin C, ®bronectin and aggrecan Fosang et al., 1996) . Apparently due to its wide substrate speci®city, the physiologic expression of MMP-13 is limited to situations, in which rapid and eective remodeling of collagenous ECM is required, i.e. fetal development of bone and postnatal bone remodeling (Johansson et al., 1997a; StaÊ hle-BaÈ ckdahl et al., 1996) . On the other hand, degradation of collagenous ECM by MMP-13 obviously plays a crucial role in destruction of normal tissue architecture in osteoarthritic cartilage (Mitchell et al., 1996; Reboul et al., 1996; Wernicke et al., 1996) , rheumatoid synovium (StaÊ hle-BaÈ ckdahl et al., 1997; Wernicke et al., 1996; Lindy et al., 1997) , chronic cutaneous ulcers (Vaalamo et al., 1997) , intestinal ulcerations and chronic periodontitis (Uitto et al., 1998) .
Fibrillar collagens are the most abundant structural components of the human connective tissues and the ability to degrade them is crucial for invasion and metastasis of neoplastic cells (Stetler-Stevenson et al., 1993; KaÈ haÈ ri and Saarialho-Kere, 1999; Westermarck and KaÈ haÈ ri, 1999) . In addition, type I collagen expression by stromal ®broblasts of malignant tumors is often activated, possibly as a host attempt to wall o the tumor (Zhu et al., 1993; Kauppila et al., 1996) . The wide substrate speci®city of MMP-13 clearly makes it a potentially useful proteolytic tool for invading tumor cells, and in fact, the expression of MMP-13 has been recently documented in invasive tumors, i.e. breast carcinomas (Freije et al., 1994; Heppner et al., 1996; UrõÂ a et al., 1997) , squamous cell carcinomas (SCCs) of the head and neck (Johansson et al., 1997b; Airola et al., 1997; Cazorla et al., 1998) , and vulva (Johansson et al., 1999) , malignant melanomas (Airola et al., 1999) , and chondrosarcomas (UrõÂ a et al., 1998) . In SCCs of the skin, oral cavity, pharynx, larynx, and vulva MMP-13 is expressed primarily by tumor cells at the invading edge of the tumor and its expression correlates with the invasion capacity of the tumors (Johansson et al., 1997b (Johansson et al., , 1999 Airola et al., 1997; Cazorla et al., 1998) . In contrast, no MMP-13 expression is noted in premalignant tumors of the skin (Airola et al., 1997) , in re-epithelializing epidermis (Vaalamo et al., 1997) , intact epidermis (Johansson et al., 1997b; Airola et al., 1997) , oral mucosa (Johansson et al., 1997b) , vulvar epithelium (Johansson et al., 1999) , or normal keratinocytes in culture (Johansson et al., 1997c) , indicating that MMP-13 expression is speci®c for transformed squamous epithelial cells.
In®ltration of in¯ammatory cells is a characteristic stromal reaction in many neoplastic tumors including SCCs (Johansson et al., 1997b (Johansson et al., , 1999 Airola et al., 1997) and it is likely that interaction of in¯ammatory cells with tumor and stromal cells modulates tumor invasion. For example, MMP-13 expression by SCC cells is potently enhanced by tumor necrosis factor-a (TNF-a) and transforming growth factor-b (TGF-b) (Johansson et al., 1997b (Johansson et al., , 1999 . Tumor-in®ltrating lymphocytes in SCCs express interferon-g (IFN-g), a Th1 cell-derived cytokine, which inhibits proliferation of SCC cells (Kim et al., 1995; Arany et al., 1998) . IFN-g also inhibits expression of type I collagen and elastin by dermal ®broblasts (KaÈ haÈ ri et al., 1990 (KaÈ haÈ ri et al., , 1992 and upregulates MMP-1 and stromelysin-1 (MMP-3) expression in normal human epidermal keratinocytes (Tamai et al., 1995) . In the present study, we show that IFN-g potently inhibits expression of MMP-13 and MMP-1, as well as invasion by transformed keratinocytes. We also show that in these cells IFN-g signaling involves activation of ERK1,2 pathway, which in part mediates activation of STAT1 by serine-727 phosphorylation and suppression of MMP-13 expression. These observations identify a novel antineoplastic role for IFN-g as a potent inhibitor of collagenolytic activity and invasion of transformed squamous epithelial cells, suggesting selective activation of IFN-g signaling pathway as a potent way of inhibiting invasion and growth of SCCs.
Results

Expression of MMP-13 and MMP-1 by transformed keratinocytes is inhibited by IFN-g
We have previously shown that collagenase-3 (MMP-13) is speci®cally expressed by transformed keratinocytes, i.e. tumor cells at the invading edge of SCCs of the head and neck and vulva (Johansson et al., 1997b (Johansson et al., , 1999 Airola et al., 1997; Cazorla et al., 1998) . The histology of SCCs is characterized by marked in®ltration of in¯ammatory cells, which may be a source of proteolytic enzymes as well as cytokines/ growth factors capable of stimulating MMP-13 expression by SCC cells, e.g. TNF-a and TGF-b (Johansson et al., 1997b (Johansson et al., , 1999 . Tumor in®ltrating lymphocytes in SCCs express IFN-g (Kim et al., 1995; Arany et al., 1998) , which can inhibit proliferation of SCC cells (Schuger et al., 1990) and stimulate production of MMP-1 and MMP-3 by normal epidermal keratinocytes (Tamai et al., 1995) . To elucidate the possible role of IFN-g in SCC invasion, we ®rst treated transformed keratinocytes with dierent concentrations of IFN-g and determined their MMP-13 and MMP-1 expression. Treatment of a metastatic human skin SCC cell line UT-SCC-7 with IFN-g (10 U/ml) resulted in marked reduction (80%) in MMP-13 mRNA levels, and the maximal inhibition (88 and 92%) was noted with concentrations 50 and 100 U/ml, respectively ( Figure 1a) . Similarly, MMP-13 mRNA abundance was potently suppressed by IFN-g in A-5 cells, a ras-transformed HaCaT keratinocyte line, the maximal inhibition noted with concentration 100 U/ml (Figure 1b) . A 24 h treatment with IFN-g (100 U/ml) also resulted in marked suppression (90%) of proMMP-13 production by UT-SCC-7 cells ( Figure  1c ) and A-5 cells (not shown).
In contrast to normal human epidermal keratinocytes (Tamai et al., 1995) , treatment of both UT-SCC-7 and A-5 cells with IFN-g potently inhibited expression of MMP-1 (Figure 1 ). The maximal inhibition of MMP-1 mRNA abundance noted with 100 U/ml of IFN-g was 72% in UT-SCC-7 cells and 87% in A-5 cells (Figure 1a, b) . In addition, production of proMMP-1 was potently (by 90%) inhibited by IFN-g in UT-SCC-7 cells ( Figure 1c ) and A-5 cells (not shown).
The eect of IFN-g on viability of transformed keratinocytes
To exclude the possibility that the reduction in MMP-13 and MMP-1 production by IFN-g would be due to reduced cell viability we determined the number of viable cells at dierent periods of time with incubation with IFN-g up to 120 h. A slight (31%) but signi®cant reduction in the number of viable A-5 cells was detected only after 120 h incubation with IFN-g, as compared to the control cells (Figure 2 ). In contrast, IFN-g slightly (by 14%), but signi®cantly reduced the number of viable UT-SCC-7 cells at 48 h and by 120 h the cell number was reduced by 52% (Figure 2 ). However, it should be noted, that IFN-g did not aect viability of either A-5 or UT-SCC-7 cells during the ®rst 24 h of incubation, indicating that its inhibitory eect on MMP-13 and MMP-1 expression after 24 h incubation is not due to reduction in cell number.
IFN-g inhibits transcription of MMP-13 and MMP-1 genes
To determine, whether IFN-g inhibits transcription of MMP-13 and MMP-1 genes in transformed keratinocytes we performed nuclear run-on assays using nuclei isolated from A-5 cells treated with IFN-g (100 U/ml) A-5 cells were also transiently transfected with human MMP-13 promoter/CAT constructs containing MMP-13 promoter fragments spanning the region from 71004 bp to 756 bp (PendaÂ s et al., 1997) and subsequently treated with IFN-g. All MMP-13 promoter constructs displayed detectable activity in untreated A-5 cells, but their activity was not reduced by IFN-g (not shown) suggesting that this fragment of the 5'-regulatory region of human MMP-13 gene does not contain all elements critical for IFN-g response, or that chromatin structure may be required for this response.
IFN-g inhibits enhancement of MMP-13 expression by TGF-b and TNF-a
Given the potent inhibition of MMP-13 expression by IFN-g, we also examined its eect on MMP-13 production in combination with TGF-b1 and TNF-a, known to stimulate expression of MMP-13 in SCC cells (Johansson et al., 1997b (Johansson et al., , 1999 
IFN-g inhibits stimulation of 92 kDa gelatinase production by TGF-b and TNF-a
As invasive tumor cells of SCCs of the head and neck and vulva express 92 kDa gelatinase (MMP-9) (Pyke et al., 1992; Johansson et al., 1999) , we also examined the regulation of gelatinolytic activity of transformed keratinocytes by IFN-g. As shown in Figure 5 , treatment with IFN-g had no marked eect on basal production of MMP-9 or MMP-2 by cultured A-5 cells. Treatment of the cells with TGF-b and TNF-a enhanced MMP-9 production 7.6-fold and 12-fold, respectively, and the up-regulatory eect of both was potently inhibited by IFN-g ( Figure 5 ). Production of Figure 2 The eect of IFN-g on cell viability. A-5 and UT-SCC-7 cells were treated with IFN-g (100 U/ml) for dierent periods of time, as indicated, and the number of viable cells was determined as described in Materials and methods. The mean+s.d. are shown (n=4). Statistical signi®cance determined by Student's t-test as compared to the corresponding untreated control cells: *P50.02, **P50.002 and ***P50.001
Figure 3 IFN-g inhibits transcription of MMP-13 and MMP-1 genes. Nuclear run-on assays were performed with nuclei from A-5 cells treated with IFN-g (100 U/ml) for time periods shown. Nascent 32 P-labeled RNA was hybridized to nitrocellulose ®lter-immobilized MMP-13, MMP-1, and GAPDH cDNA, and pBluescript vector, speci®c hybridization was visualized by autoradiography (upper panel), and quantitated by densitometry. The values for MMP-13 and MMP-1 gene transcription were corrected for GAPDH transcription in the same samples and are shown respective to transcription rate at time point 0 h (1.00) (lower panel). The values shown are mean of two independent experiments MMP-2 was also slightly (2.5-fold) enhanced by TGFb, but in contrast to MMP-9, was not inhibited by IFN-g ( Figure 5 ).
IFN-g inhibits invasion of A-5 cells
As IFN-g potently inhibits the expression of MMP-13, MMP-1, and MMP-9 we also examined its eect on the invasion capacity of transformed epidermal keratinocytes using A-5 cells as a model. Treatment of A-5 cells with TNF-a and TGF-b markedly enhanced their invasion through type I collagen and this eect was potently inhibited by IFN-g (100 U/ ml), most likely due to its ability to inhibit the collagenolytic capacity of A-5 cells (Table 1) . In parallel, invasion of A-5 cells through reconstituted basement membrane (Matrigel) was stimulated by TNF-a and TGF-b although to a lesser extent than invasion through collagen (Table 1 ). In accordance with the ability of IFN-g to abrogate induction of MMP-9 production, it also potently inhibited invasion of A-5 cells through Matrigel in the presence of TNF-a or TGF-b (Table 1) .
Activation of STAT1 by IFN-g is mediated in part by ERK1,2 pathway
Binding of IFN-g to its cell surface receptors results in oligomerization of receptor subunits and in subsequent activation of receptor-associated tyrosine kinases JAK1 and JAK2, which then activate cytoplasmic transcription factor STAT1 through tyrosine (Tyr-701) phosphorylation (see Stark et al., 1998) , resulting in dimerization, nuclear translocation, and DNA binding of STAT1. In addition, phosphorylation of a speci®c serine residue (Ser-727) is required for maximal transactivating capacity of STAT1 (Wen et al., 1995) . In this context, we determined the activation of STAT1 by IFN-g in transformed keratinocytes with Western blot analysis using antibodies speci®c for Tyr-701-phosphorylated STAT1 and Ser-727-phosphorylated STAT1. Treatment of A-5 cells with IFN-g resulted in rapid (15 min) Tyr-701 phosphorylation of STAT1 and this activation lasted at least 6 h ( Figure 6a ). IFNg treatment also resulted in phosphorylation of Ser-727 of STAT1, although with somewhat slower kinetics than phosphorylation of Tyr-701 ( Figure 6a ). As noted with Tyr-701, the activation was rather persistent, since it was still detectable after 6 h (Figure 6a ). Stimulation of cells with interferons activates ERK1,2 MAPK pathway (Raf/MEK1,2/ERK1,2), resulting in phosphorylation of Ser-727 in STAT1 (Stark et al., 1998; Wen et al., 1995; David et al., 1995; Singh et al., 1996) . To examine the role of distinct MAPKs in IFN-g signaling in transformed keratinocytes we determined the activation of ERK1,2, JNK/ SAPK, and p38 by Western blot analysis using antibodies speci®c for phosphorylated, activated forms of these MAPKs. Exposure of A-5 cells to IFN-g (100 U/ml) rapidly and transiently activated ERK1,2 at 15 and 30 min and this activation was entirely inhibited by blocking the ERK1,2 pathway by PD98059, a speci®c inhibitor of MEK1,2 (Dudley et al., 1995) (Figure 6b ). In contrast, IFN-g did not activate JNK/SAPK or p38 MAPK in these cells (not shown). In parallel, addition of PD98059 to the cells in combination with IFN-g also partially (by 42 ± 56%) prevented Ser-727 phosphorylation of STAT1, but had no eect on Tyr-701 phosphorylation (Figure 6b ). These results show that activation of STAT1 by IFN-g in transformed keratinocytes is mediated in part via ERK1,2 pathway.
Suppression of MMP-13 expression by IFN-g in A-5 cells is mediated via ERK1,2 pathway
To elucidate the role of ERK1,2 in IFN-g-elicited suppression of MMP-13 and MMP-1 expression we blocked ERK1,2 pathway by adding PD98059 to A-5 cells prior to treating them with IFN-g. As shown in Figure 7 , IFN-g alone reduced MMP-13 mRNA abundance by 99%, whereas in the presence of PD98059 the IFN-g-elicited suppression of MMP-13 mRNA levels was only 59%, indicating that the activation of ERK1,2 plays an important role in inhibition of MMP-13 expression by IFN-g. In contrast, PD98059 further augmented suppression of MMP-1 mRNA abundance by IFN-g, indicating that ERK1,2 pathway plays a distinct role in the regulation of MMP-13 and MMP-1 expression in transformed keratinocytes. This notion is also supported by the a b Figure 6 Activation of STAT1 by IFN-g in transformed keratinocytes is mediated in part by ERK1,2 MAPK. (a) A-5 cells were treated in serum free medium with IFN-g (100 U/ml) for time periods indicated. Activation of STAT1 was determined by Western blot analysis of cell lysates using antibodies speci®c for phospho-Serine-727-STAT1 (pSTAT1(Ser727)) or phosphoTyrosine-701-STAT1 (pSTAT1(Tyr701)). (b) A-5 cells were treated with IFN-g (100 U/ml), for dierent periods of time, as indicated, either without or with PD98059 (40 mM) added 1 h prior to IFN-g. Activation of ERK1/2 was determined by Western blot analysis using antibody speci®c for phosphorylated ERK1/2 (pERK1/2) and activation of STAT1 was determined as in (a). The levels of activated STAT1 and ERK1/2 were quantitated by densitometric scanning and are shown below the Western blots relative to levels at time point 0 h (1.0). Migration positions of molecular weight markers (in kDa) are shown on the left Figure 7 Inhibition of MMP-13 expression by IFN-g in A-5 cells is mediated via ERK1,2. A-5 cells were treated with IFN-g (100 U/ml) or PD98059 (40 mM) alone or in combination, as indicated. MMP-13 and MMP-1 mRNA levels were determined by Northern blot hybridizations (upper panel). MMP-13 and MMP-1 mRNA levels were quantitated by densitometry and normalized to GAPDH mRNA abundance in same samples. The mRNA levels are shown as percentages of those in the untreated cells (lower panel) observation that PD98059 alone inhibits MMP-1 expression by 58%, but somewhat enhances MMP-13 mRNA abundance (Figure 7 ).
Discussion
A characteristic feature of malignant tumors of distinct histogenetic origin is stromal host response, histologically detected as in®ltration of in¯ammatory cells in tumor tissue and peritumoral stroma. In¯ammatory cells may produce factors, e.g. TNF-a and TGF-b, which can stimulate production of invasion-associated proteinases by tumor and stromal cells. On the other hand, tumor cells express factors, such as IL-10 and FasL, which may play a role in evading the local immune response against the tumor (Kim et al., 1995; Moers et al., 1999; Lee et al., 1998) . IFN-g is a Th1 cell-derived cytokine, which plays an important role in host defense and is expressed by tumor in®ltrating lymphocytes in SCCs (Kim et al., 1995; Arany et al., 1998) . Although long-term exposure of SCC cells to IFN-g has been shown to inhibit proliferation of SCC cells (Schuger et al., 1990) , its role in tumor invasion is not known. IFN-g has been shown to enhance expression of MMP-1 and MMP-3 and inhibit expression of MMP-9 by normal human keratinocytes (Tamai et al., 1995; MaÈ kelaÈ et al., 1998) . In addition, IFN-g has been shown to augment TNF-a induced production of MMP-1 by dermal ®broblasts (Westermarck et al., 1995) and inhibit expression of MMP-1 and MMP-3 in response to interleukin-1 (Varga et al., 1995) .
In the present study we show for the ®rst time, that IFN-g potently suppresses abundant basal expression of MMP-13 and MMP-1 by transformed human epidermal keratinocytes and also abrogates enhancement of MMP-13, MMP-1, and MMP-9 expression by these cells in response to TNF-a and TGF-b. In addition, IFN-g also potently inhibits invasion of transformed keratinocytes through type I collagen and reconstituted basement membrane (Matrigel). Although invasion of tumor cells also requires enhanced cell motility, which is inhibited by IFN-g (Schuger et al., 1990) , it is evident that cells can not migrate through native type I collagen without degrading it ®rst by collagenolytic MMPs, i.e. MMP-13 or MMP-1. Therefore, it is likely that the ability of IFN-g to inhibit invasion of transformed keratinocytes through collagen gel re¯ects reduction in their MMP-13 and MMP-1 production. In addition, TNF-a and TGF-b-elicited stimulation of A-5 cell invasion through Matrigel was entirely abrogated by IFN-g most likely due to inhibition of MMP-9 production. However, as MMP-13 also degrades type IV collagen (KnaÈ uper et al., 1997) , it is possible that reduction in MMP-13 production also impairs the ability of transformed keratinocytes to invade through basement membrane. Together these observations clearly show, that IFN-g plays an important role in limiting the invasion capacity of transformed keratinocytes.
Triggering IFN-g signaling results in activation of STAT1 through phosphorylation of Tyr-701 by receptor-associated tyrosine kinases JAK1 and JAK2 (see Stark et al., 1998) . Our observations show, that IFN-g treatment of A-5 and UT-SCC-7 cells results in rapid and persistent phosphorylation of Tyr-701 residue of STAT1. Phosphorylation of Ser-727 is also required for maximal trans-activation capacity of STAT1 (see Stark et al., 1998) . In the present study, treatment of transformed keratinocytes with IFN-g also resulted in rapid phosphorylation of Ser-727 of STAT1, although with somewhat delayed kinetics, as compared to Tyr-701 phosphorylation. Interestingly, IFN-g rapidly and transiently activates ERK1,2 in A-5 cells and inhibition of ERK1,2 activation with PD98059 results in approximately 50% reduction in Ser-727 phosphorylation of STAT1. In addition, blocking ERK1,2 activation also partially (by approximately 50%) inhibited suppression of MMP-13 expression by IFN-g, indicating that ERK1,2 MAPK pathway plays an inhibitory role in MMP-13 expression. Although IFN-g inhibited transcription of the endogenous MMP-13 gene of A-5 cells in nuclear runon assays, we did not detect suppression of MMP-13 promoter activity in transient transfections using promoter/CAT constructs containing up to 1 kb of the 5'-¯anking regulatory region of the human MMP-13 gene, suggesting that the IFN-g responsive elements reside outside this region, or that chromatin structure is required for this response.
Binding of STAT1 homodimer to its cognate binding element, gamma-activated sequence (GAS) in IFN-g responsive promoters usually results in up-regulation of transcription and this may be mediated by ERK1,2 pathway (Stark et al., 1998; Wen et al., 1995; David et al., 1995; Singh et al., 1996) . However, there is recent evidence for the role of STAT1 in IFN-g-elicited inhibition of the expression of basement membrane heparan-sulfate proteoglycan perlecan (Sharma and Iozzo, 1998) . In this context, it is interesting to note that STAT1 has recently been shown to function as a scaold for IFN-g elicited activation of Raf-1 and that this adaptor function of STAT1 is dependent on its Tyr-701 phosphorylation (Stancato et al., 1998) . It is therefore possible that inhibition of MMP-13 expression by IFN-g does not necessarily involve direct suppression of MMP-13 gene transcription by STAT1 but that STAT1 plays a role in the activation of Raf-1/MEK1,2/ ERK1,2 pathway by IFN-g.
An interesting observation in the present study was that activation of ERK1,2 MAPK pathway plays an inhibitory role in MMP-13 expression. In addition, inhibition of the endogenous ERK1,2 activation by PD98059 in fact slightly enhanced basal MMP-13 expression con®rming the inhibitory role of ERK1,2 in MMP-13 expression in transformed keratinocytes. These observations are in accordance with our recent observations demonstrating an inhibitory role for ERK1,2 pathway in the expression of MMP-13 in dermal ®broblasts cultured within collagen gel (Ravanti et al., 1999) . Together these results suggest that activation of STAT1 by Ser-727 phosphorylation by ERK1,2, or by ERK1,2-independent pathway plays an important role in inhibition of MMP-13 expression.
Interestingly, expression of MMP-1 was suppressed by blocking the ERK1,2 pathway by MEK1,2 inhibitor PD98059, indicating a distinct role for ERK1,2 pathway in the regulation of MMP-13 and MMP-1. This observation is in agreement with recent studies with PD98059, demonstrating that ERK1,2 pathway mediates activation of MMP-1 expression in ®broblasts (Reunanen et al., 1998; Westermarck et al., 1998) and MMP-9 expression in transformed keratinocytes (Gum et al., 1997) . Interestingly, a recent study demonstrated that IFN-g inhibits TGF-b signaling in ®brosarcoma cells by inducing expression of SMAD7, an inhibitory member of the SMAD transcription factor family (Ulloa et al., 1999) . However, the inhibitory eect of IFN-g on TGF-b-elicited transcriptional activation or SMAD7 induction was not dependent on ERK1,2 activation (Ulloa et al., 1999) . Therefore, it is likely that SMAD7 does not play a major role in IFN-g-elicited inhibition of MMP-13 expression, which is markedly dependent on the activity of ERK1,2 pathway.
Previous observations show, that IFN-g inhibits proliferation of normal and transformed keratinocytes in culture (Schuger et al., 1990; MaÈ kelaÈ et al., 1998) . In addition, inhibition of proliferation and induction of apoptosis in colon adenocarcinoma cells involves activation of STAT1 and induction of Fas and FasL expression (Xu et al., 1998) . In our experiments, IFN-g also signi®cantly reduced the number of viable A-5 cells at 120 h of incubation. However, treatment of UT-SCC-7 cells with IFN-g reduced the number of viable cells more potently, initially at 48 h of incubation with additional reduction noted up to 120 h. These results clearly show that the inhibitory eect of IFN-g on MMP-13 and MMP-1 expression noted during the ®rst 24 h of incubation is not due to cytotoxicity. Furthermore, these observations demonstrate the bimodal antineoplastic eect of IFN-g on transformed keratinocytes: initial inhibition of cell invasion due to suppression of the expression of invasion-associated MMPs, which is followed by inhibition of cell proliferation and induction of apoptosis at prolonged exposure. This combined anti-invasive and proapoptotic mode of action of IFN-g is in accordance with recent observations showing that high expression of IFN-g in SCCs correlates with favorable prognosis (Arany et al., 1998; Tartour et al., 1998) .
Invasion of malignant cells is a multistep process, in which cellular motility is coupled to proteolysis and involves interactions with the extracellular matrix (Stetler-Stevenson et al., 1993) . MMPs have been implicated in growth and invasion of various tumors, including SCCs and degradation of ®brillar collagens by collagenolytic MMPs is essential for invasion of malignant cells, as ®brillar collagens of type I and III constitute the majority of the stromal ECM (StetlerStevenson et al., 1993) . Therefore, inhibition of MMP activity may appear as a potent way of inhibiting tumor growth and invasion, and in fact, several synthetic small molecule MMP inhibitors are at present in clinical trials to inhibit growth and invasion of various malignant tumors (KaÈ haÈ ri and SaarialhoKere, 1999). In addition, overexpression of tissue inhibitor of metalloproteinases (TIMP)-1, -2, and -3 appears an eective way of inhibiting the invasion of malignant cells . Our results together with recent observations (Reunanen et al., 1998; Ravanti et al., 1999; Westermarck et al., 1998; Gum et al., 1997) indicate that modulation of the activity of distinct MAPKs may serve as a potent way of inhibiting MMP expression and invasion. In conclusion, the results of the present study show that selective activation of the IFN-g signaling pathway may serve as a speci®c way of potently suppressing invasion and metastasis of malignant squamous epithelial cells in vivo.
Materials and methods
Reagents and antibodies
Human recombinant IFN-g was obtained from Promega (Madison, WI, USA). Human recombinant TNF-a and TGFb1 were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Speci®c MEK1,2 inhibitor PD98059 (2'-amino-3'-methoxy¯avone) was obtained from Calbiochem (San Diego, CA, USA). Antibodies speci®c for Tyr-701 phosphorylated STAT1 and Ser-727 phosphorylated STAT1 were obtained from Upstate Biotechnology (Lake Placid, NY, USA). Phosphospeci®c ERK1,2, JNK/SAPK, and p38 MAPK antibodies were purchased from New England Biolabs (Beverly, MA, USA).
Cell cultures
Human SCC cell line UT-SCC-7, established from metastasis of cutaneous SCC (Johansson et al., 1997b) was cultured in DMEM supplemented with 6 mmol/L glutamine, nonessential amino acids, and 10% fetal calf serum (FCS). A-5 cells, a ras-transformed tumorigenic HaCaT cell line (Boukamp et al., 1990) was cultured in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% FCS.
RNA analysis
Total RNA was isolated from cells using modi®ed single-step phenol/chloroform extraction (Chomczynski and Sacchi, 1987) . Aliquots of total RNA (15 ± 20 mg) were analysed by Northern blot hybridizations as described previously (Johansson et al., 1997c) , using cDNA probes labeled with a-32 P-dCTP by random priming. For hybridizations, MMP-13 cDNA fragments covering the coding region and part of the 3'-untranslated region of the human MMP-13 cDNA, altogether 1.9 kb were used (Johansson et al., 1997c) . In addition, a 2.0 kb human MMP-1 cDNA (Goldberg et al., 1986) , and a 1.3 kb rat GAPDH cDNA (Fort et al., 1985) were used as probes. The 32 P-labeled cDNA-mRNA hybrids were visualized by autoradiography, quantitated by scanning densitometry and corrected for the levels of GAPDH transcripts in the same RNA samples.
Transcriptional nuclear run-on analyses
In vitro nuclear run-on analyses were performed with equal number of isolated nuclei (7610 6 per reaction) in the presence of 100 mCi of [a-32 P]UTP (3000 Ci/mmol, Amersham, UK), as previously described (Johansson et al., 1997c) . Radiolabeled RNA was hybridized with 2 mg of nitrocellulose-®xed plasmids speci®c for MMP-13 (Johansson et al., 1997c) MMP-1 (Goldberg et al., 1986) and GAPDH (Fort et al., 1985) and pBluescript. The hybridization and washing conditions used were as previously described (Johansson et al., 1997c) . Speci®c hybridization was visualized by autoradiography and the levels of MMP-13 and MMP-1 transcripts were quantitated by densitometric scanning and corrected for the levels of GAPDH transcripts in the same samples.
Transient transfections
A-5 cells were transiently transfected with human MMP-13 promoter/chloramphenicol acetyl transferase (CAT) constructs 71004CAT, 7402CAT, 756CAT and 7402delPEA3CAT (PendaÂ s et al., 1997). Transfections were performed by adding mixture of DNA (4 mg per 60 mm dish) and DOTAP (Boehringer Mannheim) to the cells for 5 h according to manufacturer's instructions. The culture medium (DMEM and 1% FCS) was changed, IFN-g (100 U/ml) was added 2 h later, and the incubations were continued for 48 h. Cells were lyzed and CAT activity was measured as an index of promoter activity, as described previously (Westermarck et al., 1997) . Transfection eciency was monitored by co-transfecting the cells with 1 mg of RSV/ b-galactosidase construct and correcting the CAT activities for b-galactosidase activity (Westermarck et al., 1997) .
Assay of MMP-13 and MMP-1 production Equal aliquots of the conditioned media of cells were fractionated on 7.5% SDS ± PAGE, transferred to Hybond ECL ®lter (Amersham), and the amounts of MMP-13 and MMP-1 were determined by Western blot analysis using polyclonal antibodies against human recombinant MMP-13 (Freije et al., 1994) in dilution 1 : 1000 and human MMP-1 (kindly provided by Dr H Birkedal-Hansen, NIDR, Bethesda, MD, USA) in dilution 1 : 2000, followed by detection of speci®cally bound primary antibodies with peroxidase-conjugated secondary antibodies visualized by enhanced chemiluminescence (ECL) (Amersham).
Gelatinase zymography
Aliquots of conditioned media were fractionated on 10% SDS ± PAGE containing 1 mg/ml gelatin (G-6269; Sigma) and 0.5 mg/ml 2-methoxy-2,4-diphenyl-3(2H)-furanone (Fluka 645989) (O'Grady et al., 1984) . The gels were washed for 30 min in 50 mM Tris, 0.02% NaN 3 and 2.5% Triton X-100, pH 7.5 and for 30 min in the same buer supplemented with 5 mM CaCl 2 and 1 mM ZnCl 2 (Heussen and Dowdle, 1980) . The gels were then incubated in 50 mM Tris, 0.02% NaN 3 , 5 mM CaCl 2 and 1 mM ZnCl 2 for 24 h at 378C, ®xed in 50% methanol/7% acetic acid, stained with 0.2% Coomassie Blue G250 and photographed.
Invasion assays
The invasion assays were performed as previously described . Cell culture inserts (Falcon 3097, Becton Dickinson) with 8.0 mm pore size were coated with 50 mg of reconstituted basement membrane (Matrigel, Becton Dickinson), or with a 1 mm thick type I collagen gel prepared by mixing eight volumes of collagen solution (Cellon Bovine Dermal Collagen, Cellon, Strassbourg) with 1/10 volumes of 106DMEM and 1/10 volumes of 0.2 M HEPES/0.04 M NaOH, pH 7.3 and allowed to polymerize at 378C for 40 min. For invasion assays, cells (2610 5 /chamber) suspended in DMEM containing 0.1% BSA were placed on top of the gel in the upper chamber in a ®nal volume of 200 ml, with DMEM (700 ml) containing 10% FCS as chemoattractant in the lower chamber. After 24 h (Matrigel) or 48 h (type I collagen), cells on the upper surface were gently removed with a cotton bud and the invaded cells on the lower surface were ®xed in 2% paraformaldehyde, counterstained with 0.1% crystal violet and counted.
Determination of viable cell number
For cell viability assays 1610 4 cells were seeded on 96-well plates and incubated for dierent periods of time in the presence of IFN-g (100 U/ml). The number of viable cells was determined by CellTiter 96 TM AQ ueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI, USA) according to manufacturer's instructions.
Determination of STAT1 and MAPK activation
Cells were treated with IFN-g (100 U/ml) for dierent periods of time, lyzed in 100 ml of sample buer (50 mM Tris-HCl, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EGTA, 1 mM PMSF, 0.0001% aprotinin, 0.0001% pepstatin, 1 mM Na 3 VO 4 1 mM NaF), sonicated, heated at 958C for 5 min, fractionated on 10% SDS ± PAGE, and transferred to Hybond ECL membrane (Amersham, UK). Western blot analysis was performed as previously described (Reunanen et al., 1998) with antibodies speci®c for Tyr-701-phosphorylated STAT1, Ser-727-phosphorylated STAT1, ERK1,2, JNK/SAPK, and p38 in dilution 1 : 1000. Speci®c binding of antibodies was detected with peroxidase conjugated secondary antibodies and visualized by ECL.
